ClinicalTrials.gg

Program

camizestrant

Also written as “AZD9833”, “Camizestrant” and “AZD9833 with palbociclib”.

Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis · Lymphoma, Follicular, led by AstraZeneca.

Furthest: phase 3, since Dec 23, 202018 company-led studies, 9 open or runningNext primary completion: Apr 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca189 open or runningphase 3since Dec 23, 2020Jul 6, 2018Apr 20, 2027phase 3 · NCT05774951

Also a collaborator on its studies: icon-plc, quotient-sciences and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 6, 2018.

  1. Sep 8, 2020Phase 2 study in Breast NeoplasmsNCT04588298 · 135 enrolled · Georgia, Mexico, United Kingdom
  2. Sep 8, 2020Phase 1 study in Breast NeoplasmsNCT04546347 · 32 enrolled · United Kingdom
  3. Dec 23, 2020Phase 3 study in Neoplasm MetastasisNCT04711252 · 1,371 enrolled · United States, Austria, Belgium and more
  4. Mar 24, 2021Phase 1 study in Breast NeoplasmsNCT04818632 · 28 enrolled · China
  5. Jun 30, 2021Phase 3 study in Neoplasm MetastasisNCT04964934 · 315 enrolled · United States, Australia, Austria and more
  6. May 4, 20222 phase 1 studies in Breast NeoplasmsNCT05364255, NCT05438303
  7. Sep 20, 2022Phase 1 study in Breast NeoplasmsNCT05551897 · 14 enrolled · United Kingdom
  8. Jan 25, 2023Phase 1 study in Lymphoma, FollicularNCT05790304 · 22 enrolled · United States, Bulgaria, Slovakia
  9. Feb 16, 2023Phase 3 study in Breast NeoplasmsNCT05774951 · 4,300 planned · United States, Argentina, Australia and more
  10. May 17, 2023Phase 3 study in Breast NeoplasmsNCT05952557 · 5,511 enrolled · United States, Argentina, Australia and more
  11. Mar 25, 2024Phase 3 study in Advanced Breast CancerNCT06380751 · 788 planned · United States, Argentina, Australia and more
  12. Aug 7, 2024Phase 1 study in Breast NeoplasmsNCT06547164 · 40 enrolled · United Kingdom
  13. Feb 16, 2026Phase 2 study in Advanced Breast CancerNCT07427394 · 24 planned · United States, United Kingdom
  14. May 12, 2026Phase 3 study in Neoplasm MetastasisNCT07647328 · 150 planned · United States, France, Germany and more

Ahead

  1. Apr 20, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05774951
  2. Dec 28, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07427394
  3. Feb 28, 2029Primary completion: phase 3 study in Neoplasm MetastasisNCT07647328
  4. Dec 18, 2029Primary completion: phase 3 study in Advanced Breast CancerNCT06380751

TargetBeta

ESR1 →read by rule
“An orally available selective estrogen receptor degrader (SERD), ”NCIt, by rule
“Estrogen receptor alpha degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07647328Neoplasm Metastasis · United States, France, Germany and more3RecruitingFeb 28, 2029150
NCT07427394Advanced Breast Cancer · United States, United Kingdom2RecruitingDec 28, 202724
NCT06547164Breast Neoplasms · United Kingdom1CompletedAug 20, 202540
NCT06380751Advanced Breast Cancer · United States, Argentina, Australia and more3RecruitingDec 18, 2029788
NCT05952557Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 4, 20305,511
NCT05774951Breast Neoplasms · United States, Argentina, Australia and more3RecruitingApr 20, 20274,300
NCT05790304Lymphoma, Follicular · United States, Bulgaria, Slovakia1CompletedFeb 22, 202422
NCT05551897Breast Neoplasms · United Kingdom1CompletedDec 28, 202214
NCT05438303Breast Neoplasms · United States1CompletedDec 13, 202259
NCT05364255Breast Neoplasms · United Kingdom1CompletedJun 20, 20226
NCT04964934Neoplasm Metastasis · United States, Australia, Austria and more3Active, not recruitingJun 30, 2025315
NCT04818632Breast Neoplasms · China1CompletedSep 7, 202328
NCT04711252Neoplasm Metastasis · United States, Austria, Belgium and more3Active, not recruitingJun 26, 20261,371
NCT04588298Breast Neoplasms · Georgia, Mexico, United Kingdom2CompletedJun 19, 2023135
NCT04546347Breast Neoplasms · United Kingdom1CompletedJan 7, 202132
NCT04541433Breast Neoplasms · Japan1CompletedJul 29, 202210
NCT04214288Neoplasm Metastasis · United States, Belgium, Canada and more2Active, not recruitingAug 30, 2022240
NCT03616587Breast Neoplasms · United States, Spain, United Kingdom1Active, not recruitingSep 16, 2024396

How it is read

Names in the registry

  • “AZD9833”, 10 entries
  • “Camizestrant”, 8 entries
  • “AZD9833 with palbociclib”, 3 entries
  • “AZD9833 with everolimus”, 3 entries
  • “AZD9833 with abemaciclib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.